Meu SciELO
Serviços Personalizados
Artigo
Indicadores
Citado por SciELO
Links relacionados
Similares em SciELO
Compartilhar
Gaceta Médica Espirituana
versão On-line ISSN 1608-8921
Resumo
SANCHEZ LINARES, Vladimir et al. HeberFERON in periocular basal cell carcinoma. Case series. Gac Méd Espirit [online]. 2021, vol.23, n.1, pp. 35-45. Epub 01-Abr-2021. ISSN 1608-8921.
Background:
Periocular basal cell carcinoma is a tumor lesion arising from the epidermis and hair follicles basal cells, with a high potential local destruction, can be disfiguring and invade the surrounding tissue leading to deformities or loss of function of the affected organ. In order of appearance it is most common in the lower eyelid, medial edge, upper eyelid and temporal edge.
Objective:
To describe the results of the application of HeberFERON in a case series with periocular basal cell carcinoma who attended dermatology appointment at the Policlínico Centro, from January 2017 to December 2020.
Methodology:
A series study of clinical cases with periocular basal cell carcinoma who attended the dermatology appointment at the Policlínico Centro was conducted. 17 cases with clinical, dermatoscopic and histopathological diagnosis were included. A baseline evaluation was conducted, during and 16 weeks after treatment; 10.5 IU of HeberFERON was administered 3 times a week perilesional and intradermally until completing 9 doses. The main variables were the treatment response and the presence or absence of adverse events.
Results:
Male sex, phototypocutaneous II, lower eyelid location, clinical subtype ulcerative nodule and solid histological subtype predominated, complete response was achieved in most patients. Adverse events were pain at the injection site, fever, general malaise, edema and perilesional erythema.
Conclusions:
Treatment response was favorable in most patients treated with HeberFERON.
Palavras-chave : Skin neoplasms and therapy; carcinoma basal celL and therapy; dermatitis perioral and therapy; periocular basal cell carcinoma; skin cancer non-melanoma; interferon alpha-2; HeberFERON; interferons and therapeutic use.